U.S. Healthtech Stock News

Copa Holdings (NYSE:CPA) just released its November traffic update, showing capacity up 10% and passenger traffic up 10.2% year over year, with load factor nudging higher to 86.2%. See our latest analysis for Copa Holdings. The strong November traffic update fits neatly with Copa Holdings' recent momentum, with a 1 day share price return of 3.47 percent and a robust year to date share price return of 44.81 percent. The 1 year total shareholder return of 48.17 percent underscores that...

Legend Biotech (LEGN) just released fresh long term data on its flagship CAR T therapy CARVYKTI from the CARTITUDE program in hard to treat multiple myeloma, clarifying its profile for durability, safety, and potential future revenue. See our latest analysis for Legend Biotech. Despite today’s positive CARVYKTI update, Legend Biotech’s 30 day share price return of minus 21.71 percent and one year total shareholder return of minus 35.68 percent show sentiment has been weak, but the 3.01...

Recent analyst upgrades and upbeat commentary around Cummins (CMI) have pushed the stock back into focus, as investors weigh its growing data center backup power exposure against a softer heavy truck cycle. See our latest analysis for Cummins. That backdrop helps explain why the latest share price of $506.72 sits on top of a powerful 45.76 percent year to date share price return and a 47.09 percent one year total shareholder return, signaling momentum that looks more like a sustained rerating...

Jefferies Financial Group recently faced an SEC investigation and parallel law firm probes into whether it adequately disclosed risks tied to its Point Bonita Capital trade finance exposure to bankrupt auto-parts supplier First Brands Group, while also continuing to issue multiple long-dated, callable senior unsecured notes in 2031, 2040 and 2055. The juxtaposition of fresh bond issuance and a regulatory probe into risk disclosure and internal controls raises important questions about...

In recent days, Cardinal Health reported an exceptional quarter, beating revenue and EPS expectations, while management highlighted broad-based operational strength heading into fiscal 2026. Commentary has also emphasized CEO Jason Hollar’s vision and the company’s growing exposure to higher-value areas like specialty therapies and nuclear medicine, even as potential regulatory shifts remain a key risk. With this backdrop of stronger-than-expected execution and optimistic commentary on...

If you are wondering whether Viatris at around $11.93 is a hidden value play or a value trap, you are not alone. This article is about cutting through that noise. The stock has crept higher in the short term, up about 2.4% over the last week and 14.1% over the past month, even though it is roughly flat over 1 year and still down 3.9% year to date. Part of this renewed interest has come as investors refocus on Viatris’ strategic shift toward a more streamlined, branded and complex generics...

Recent share performance and setup Littelfuse (LFUS) has quietly outperformed many industrial tech peers this year, with the stock up about 9% year to date and roughly 10% over the past year, despite some recent pullback. See our latest analysis for Littelfuse. The recent pullback after a solid 1 month share price return suggests some short term profit taking, but the 1 year total shareholder return still points to steady, if unspectacular, momentum. If you are comparing Littelfuse to what...

In December 2025, Wells Fargo & Company said it will redeem all of its Floating Rate Junior Subordinated Deferrable Interest Debentures due January 15, 2027 on January 15, 2026 at 100% of principal plus accrued interest, removing a covenant that had constrained redemptions of its 3.90% Fixed Rate Reset Non-Cumulative Perpetual Class A Preferred Stock, Series BB. At the same time, Wells Fargo has been active in issuing new callable senior and subordinated unsecured notes across maturities out...

Assurant recently reported quarterly results that exceeded earnings and revenue expectations, while expanding its mobile device protection and extended service contract programs through new financial services partnerships. This combination of consistent earnings outperformance and broader protection offerings across connected devices, homes, and automobiles has reinforced confidence in Assurant’s business model resilience. We’ll now explore how this continued earnings outperformance,...

Reynolds Consumer Products recently reported year-on-year revenue growth of 2.3%, surpassing analysts’ expectations by 3.4% and delivering improved results across all four business units, with revenue guidance for the next quarter also coming in ahead of consensus. This combination of better-than-expected revenue performance and stronger forward guidance underlines how share gains across most categories are contributing to Reynolds’ current momentum. We’ll now look at how Reynolds’...

Host Hotels & Resorts recently reported third-quarter 2025 earnings with earnings per share of US$0.23 versus expectations of US$0.04, and completed a US$400 million 4.250% Senior Notes due 2028 offering that is expected to raise about US$395 million in net proceeds. This combination of a stronger-than-expected quarter and fresh funding expands the company’s financial flexibility to reinvest in its premium hotel portfolio and support ongoing capital projects. Next, we’ll examine how the...

Advance Auto Parts (AAP) has quietly slid again, with the stock down about 2 % on the day and roughly 31 % over the past 3 months, putting its turnaround story back under the microscope for investors. See our latest analysis for Advance Auto Parts. Zooming out, the recent slide adds to a tough stretch, with a roughly 19 percent 1 month share price return and a year to date share price decline suggesting momentum is still fading despite some operational progress, while the 3 year total...

Children's Place (PLCE) is back in focus after a rough stretch, with a third straight quarterly loss, softer sales, and fresh financing moves that aim to steady the balance sheet and fund a broader turnaround. See our latest analysis for Children's Place. The new term loan and revolving credit line arrive against a brutal backdrop, with a 7 day share price return of minus 41.9 percent and a 1 year total shareholder return of minus 57.6 percent. This underscores that sentiment has been...

The Bank of N.T. Butterfield & Son (NYSE:NTB) just rolled out a fresh buyback plan, authorizing up to 3 million shares for 140 million dollars through 2026, which may be interpreted as a signal of management's confidence. See our latest analysis for Bank of N.T. Butterfield & Son. The new buyback comes after a strong run, with the share price up around 41 percent year to date and a robust 3 year total shareholder return of about 100 percent, suggesting momentum is still very much on the...

Origin Bancorp has been added to the Russell 1000 Index, placing the regional lender alongside larger US-listed companies that the index tracks. This index inclusion raises Origin Bancorp’s visibility with institutional investors that track or benchmark against the Russell 1000, potentially increasing attention on its regional banking franchise. We’ll now examine how Origin Bancorp’s new Russell 1000 membership could influence its investment narrative, particularly around institutional...

ZenaTech has announced plans to open its Zena AI Baton Rouge R&D Center in early 2026, focused on secure, defense-oriented artificial intelligence and quantum computing research for the U.S. Department of War, DARPA, and other federal agencies. This move positions the company at the intersection of AI, quantum computing, and defense applications, including multi-drone coordination, secure edge intelligence, and battlefield decision-support technologies. We’ll now examine how the new Baton...

Earlier this week, Sezzle Inc. (NasdaqCM: SEZL) completed a US$50.00 million share repurchase program and then authorized a new, open-ended US$100.00 million buyback while also being added to the S&P SmallCap 600, S&P 1000, S&P 600 Financials, and S&P Composite 1500 indices. Together, the expanded buyback capacity and new index inclusions suggest Sezzle is tightening its share count while broadening its institutional investor reach. With this fresh US$100.00 million repurchase authorization...

Alight (ALIT) shares slipped after the company said Chief Financial Officer Jeremy Heaton will resign in early January, with longtime finance leader Greg Giometti stepping in as interim CFO to guide the transition. See our latest analysis for Alight. The CFO transition lands at a tough time for shareholders, with the 1 year total shareholder return down about 70 percent and the 90 day share price return sliding roughly 42 percent. This signals that momentum has clearly been fading despite...

Arthur J. Gallagher & Co. recently filed a Form 8-K under Regulation FD and, earlier this month, held an investor meeting that shared updated 2025–2026 estimates and details on net after-tax cash flows from its clean energy investments. At the same time, several research firms, including Evercore ISI and Truist, reassessed their views on the company in light of softer organic growth expectations and property pricing pressures, prompting investors to reconsider how much growth risk is already...

BKV Corporation recently announced that its Board of Directors has authorized a two-year share repurchase program of up to US$100 million of its outstanding common stock, to be funded through available cash or borrowings under its existing reserve-based lending agreement. The buyback authorization, coming shortly after a public offering that raised about US$170.3 million linked to a planned power asset acquisition, highlights how BKV is actively reshaping its capital structure and capital...

Vertex Pharmaceuticals recently reported new clinical data showing that all evaluable children aged 5–11 treated with CASGEVY achieved key endpoints in sickle cell disease and transfusion-dependent beta thalassemia, and also secured an FDA National Priority Voucher to accelerate review in this younger age group. By pairing strong pediatric efficacy signals with an expedited U.S. regulatory review pathway, Vertex is strengthening CASGEVY’s potential role in reshaping treatment for severe...

Insight Enterprises recently amended its asset-based credit agreement, lifting its revolving credit facility to the US$2.00 billions equivalent, extending its maturity to December 19, 2030, and adding more flexibility around receivables sales across multiple geographies and currencies. On the same day, the company also completed a prior repurchase plan and authorized a new US$299 million share buyback, signaling management’s confidence in liquidity and capital allocation discipline. Next,...

Immunovant (IMVT) just raised roughly $550 million through a follow on equity offering at $21 a share, a meaningful capital boost that also brings the usual dilution questions front and center for investors. See our latest analysis for Immunovant. The offering lands on top of a strong run, with a 30 day share price return of about 15 percent and a 90 day surge of more than 80 percent. The three year total shareholder return above 60 percent suggests longer term momentum has been building...

For investors wondering whether Guardant Health is still a smart buy after its massive run up, or if new investors might be late to the party, this article will walk through what the current price is really baking in. The stock has surged an eye catching 214.9% over the last year and 213.9% year to date, even if the last week and month have been relatively flat at -2.3% and 0.2% respectively. Behind those moves, investors have been reacting to a steady drumbeat of news around Guardant's...